Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2023

Open Access 01-12-2023 | ST-Segment Elevation Myocardial Infarction | Research

Favorable factors for the survival of ST-segment elevation myocardial infarction patients with medium- and high-risk thrombolysis in myocardial infarction scores

Authors: Zhengli Luo, Yuan Feng, Dan Luo, Shiyang Li, Kaiyi Xiao, Hongmei Shen, Qiang Hu

Published in: BMC Cardiovascular Disorders | Issue 1/2023

Login to get access

Abstract

Objective

ST-segment myocardial infarction (STEMI) is a time-sensitive emergency. This study screened the favorable factors for the survival of STEMI patients with medium- and high-risk thrombolysis in myocardial infarction (TIMI) scores.

Methods

According to the TIMI scores at admission, 433 STEMI patients were retrospectively and consecutively selected and allocated into low-/medium-/high-risk groups, with their general information/blood routine/biochemical indicators/coagulation indicators documented. The factors influencing the in-hospital survival of STEMI patients were analyzed using univariate and multivariate logistic regression analyses. Moreover, the predictive value of favorable factors was analyzed by receiver operating characteristics (ROC) curve, and patients were assigned into high/low level groups based on the cut-off value of these factors, with their in-hospital survival rates compared.

Results

The in-hospital survival rate of the medium-/high-risk groups was lower than that of the low-risk group. Emergency percutaneous coronary intervention (PCI), lymphocyte (LYM), total protein (TP), albumin (ALB), and sodium (Na) were independent favorable factors for in-hospital survival in the medium-/high-risk groups. Besides, LYM > 1.275 × 109/L, TP > 60.25 g/L, ALB > 34.55 g/L, and Na > 137.9 mmo1/L had auxiliary predictive value for the survival of STEMI patients with medium-/high-risk TIMI scores. Patients with high levels of LYM, TP, ALB, and Na exhibited higher in-hospital survival rates than patients with low levels.

Conclusion

For STEMI patients with medium- and high-risk TIMI scores, accepting emergency PCI and normal levels of LYM, TP, ALB, and Na were more conducive to in-hospital survival.
Appendix
Available only for authorised users
Literature
1.
Lv D, Guo Y, Zhang L, Li X, Li G. Circulating miR-183-5p levels are positively associated with the presence and severity of coronary artery disease. Front Cardiovasc Med. 2023;10:1196348.CrossRefPubMedPubMedCentral
2.
Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020;1177:1–36.CrossRefPubMed
3.
Gunlu S, Arpa A, Kayan F, Guzel T, Kilic R, Aktan A, et al. The prognostic value of ORBIT risk score in predicting major bleeding in patients with acute coronary syndrome. Thromb Res. 2023;229:258–62.CrossRefPubMed
4.
Fuentes E, Moore-Carrasco R, de Andrade Paes AM, Trostchansky A. Role of platelet activation and oxidative stress in the evolution of myocardial infarction. J Cardiovasc Pharmacol Ther. 2019;24(6):509–20.CrossRefPubMed
5.
Yildiz I, Rencuzogullari I, Karabag Y, Karakayali M, Artac I, Gurevin MS. Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction. Rev Assoc Med Bras (1992). 2022;68(6):802–7.CrossRefPubMed
6.
Frampton J, Devries JT, Welch TD, Gersh BJ. Modern management of ST-segment elevation myocardial infarction. Curr Probl Cardiol. 2020;45(3):100393.CrossRefPubMed
7.
Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015;385(9966):441–51.CrossRefPubMed
8.
Khedr A, Hennawi HA, Khan MK, Elbanna M, Jama AB, Proskuriakova E, et al. Effect of fibrinolytic therapy on ST-elevation myocardial infarction clinical outcomes during the COVID-19 pandemic: a systematic review and meta-analysis. World J Cardiol. 2023;15(6):309–23.CrossRefPubMedPubMedCentral
9.
Castro-Dominguez Y, Dharmarajan K, McNamara RL. Predicting death after acute myocardial infarction. Trends Cardiovasc Med. 2018;28(2):102–9.CrossRefPubMed
10.
Kao YT, Hsieh YC, Hsu CY, Huang CY, Hsieh MH, Lin YK, et al. Comparison of the TIMI, GRACE, PAMI and CADILLAC risk scores for prediction of long-term cardiovascular outcomes in Taiwanese diabetic patients with ST-segment elevation myocardial infarction: from the registry of the Taiwan Society of Cardiology. PLoS One. 2020;15(2):e0229186.CrossRefPubMedPubMedCentral
11.
Yang B, Bai L, Zhang Y, Cheng Y, Zhao C, Huang B, et al. The value of different short-term risk scoring models in predicting long-term death of acute myocardial infarction. J Clin Med. 2022;11(17):5054.CrossRefPubMedPubMedCentral
12.
Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, et al. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) risk score for secondary prevention in post-mi patients: a collaborative analysis of the chronic kidney disease prognosis consortium and the risk validation scientific committee. J Am Heart Assoc. 2018;7(14):e008426.CrossRefPubMedPubMedCentral
13.
Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–42.CrossRefPubMed
14.
Ozturk D, Melekoglu A, Altinbilek E, Calik M, Kosem A, Kilci H, et al. association between serum irisin levels and ST-segment elevation myocardial infarction. Int J Gen Med. 2023;16:1355–62.CrossRefPubMedPubMedCentral
15.
Zhang M, Li J, Hua C, Niu J, Liu P, Zhong G. Exploring an immune cells-related molecule in STEMI by bioinformatics analysis. BMC Med Genomics. 2023;16(1):151.CrossRefPubMedPubMedCentral
16.
Grinberg T, Bental T, Hammer Y, Assali A, Vaknin-Assa H, Wiessman M, et al. Management and outcome across the spectrum of high-risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk-score for secondary prevention. Clin Cardiol. 2021;44(11):1535–42.CrossRefPubMedPubMedCentral
17.
Hartopo AB, Puspitawati I, Mumpuni H. The ratio of circulating endothelin-1 to endothelin-3 associated with TIMI risk and dynamic TIMI risk score in ST elevation acute myocardial infarction. Can J Physiol Pharmacol. 2020;98(9):637–43.CrossRefPubMed
18.
Karabag Y, Cagdas M, Rencuzogullari I, Karakoyun S, Artac I, Ilis D, et al. Comparison of SYNTAX score II efficacy with SYNTAX score and TIMI risk score for predicting in-hospital and long-term mortality in patients with ST segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2018;34(8):1165–75.CrossRefPubMed
19.
Avci E, Kiris T, Akgun DE, Celik A, Akcay FA, Acar B, et al. Bleeding risk in patients with acute coronary syndrome in a Turkish population: results from the Turkish Acute Coronary Syndrome Registry (TACSER) study. Eur J Clin Invest. 2020;50(11):e13271.CrossRefPubMed
20.
Chacon-Diaz M, Custodio-Sanchez P, Rojas De La Cuba P, Yabar-Galindo G, Rodriguez-Olivares R, Miranda-Noe D, et al. Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country. BMC Cardiovasc Disord. 2022;22(1):296.CrossRefPubMedPubMedCentral
21.
Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y(12) Inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. 2023;81(6):537–52.CrossRefPubMed
22.
Altunova M, Karakayali M, Kahraman S, Avci Y, Demirci G, Sevinc S, et al. Systemic Immune-inflammatory index is associated with residual SYNTAX score in patients with st-segment elevation myocardial infarction. Anatol J Cardiol. 2023;27(8):472–8.CrossRefPubMedPubMedCentral
23.
Tanik VO, Cinar T, Arugaslan E, Karabag Y, Hayiroglu MI, Cagdas M, et al. The Predictive Value of PRECISE-DAPT Score for In-Hospital Mortality in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology. 2019;70(5):440–7.CrossRefPubMed
24.
Ottani F, Limbruno U, Latini R, Misuraca L, Galvani M. Reperfusion in STEMI patients: still a role for cardioprotection? Minerva Cardioangiol. 2018;66(4):452–63.PubMed
25.
Anzai A, Ko S, Fukuda K. Immune and inflammatory networks in myocardial infarction: current research and its potential implications for the clinic. Int J Mol Sci. 2022;23(9):5214.CrossRefPubMedPubMedCentral
26.
Ji Z, Liu G, Guo J, Zhang R, Su Y, Carvalho A, et al. The neutrophil-to-lymphocyte ratio is an important indicator predicting in-hospital death in ami patients. Front Cardiovasc Med. 2021;8:706852.CrossRefPubMedPubMedCentral
27.
Pashapour P, Ghaffarii S, Separham A. The relationship of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in peripheral blood with ST-segment resolution and the clinical outcomes of STEMI patients receiving thrombolytic therapy. Rom J Intern Med. 2019;57(1):47–54.PubMed
28.
Zhang S, Diao J, Qi C, Jin J, Li L, Gao X, et al. Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. 2018;18(1):75.CrossRefPubMedPubMedCentral
29.
Turkyilmaz E, Ozkalayci F, Birdal O, Karagoz A, Tanboga IH, Tanalp AC, et al. Serum albumin to creatinine ratio and short-term clinical outcomes in patients with ST-elevation myocardial infarction. Angiology. 2022;73(9):809–17.CrossRefPubMed
30.
Biccire FG, Pastori D, Tanzilli A, Pignatelli P, Viceconte N, Barilla F, et al. Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. Nutr Metab Cardiovasc Dis. 2021;31(10):2904–11.CrossRefPubMed
31.
Havranek S, Belohlavek J, Skulec R, Kovarnik T, Dytrych V, Linhart A. Long-term prognostic impact of hyponatremia in the ST-elevation myocardial infarction. Scand J Clin Lab Invest. 2011;71(1):38–44.CrossRefPubMed
Metadata
Title
Favorable factors for the survival of ST-segment elevation myocardial infarction patients with medium- and high-risk thrombolysis in myocardial infarction scores
Authors
Zhengli Luo
Yuan Feng
Dan Luo
Shiyang Li
Kaiyi Xiao
Hongmei Shen
Qiang Hu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2023
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-023-03628-7

Other articles of this Issue 1/2023

BMC Cardiovascular Disorders 1/2023 Go to the issue

Research

Fibrinolytic therapy use for ST-segment elevation myocardial infarction and long-term outcomes in China: 2-year results from the China Acute Myocardial Infarction Registry

Research

The association between blood pressure control and long-term cardiovascular outcomes in Hypertension coexistent with obstructive sleep apnea

Research

Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study

Research

Magnitude and associated factors of dyslipidemia among patients with severe mental illness in dire Dawa, Ethiopia: neglected public health concern

Research

Association of polymorphisms of renin angiotensin system and endothelial nitric oxide synthase genes with premature cardiovascular disease in an Iranian population

Research

Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits